Viridian Therapeutics(VRDN) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results - Robust execution with multiple upcoming near-term milestones, including planned Biologics License Application (BLA) submission for veligrotug on track in 2H 2025 and expected U.S. commercial launch in 2026 - - Breakthrough Therapy Designation (BTD) for veligrotug announced in May 2025, a designation granted by the Food and Drug Administration (FDA) to drug candidates where clinical evidence show ...